Director, Global Therapeutic Area Lead StatisticianCSL Behring, King of Prussia, PA, USAKing of Prussia, Pennsylvania, United States
OC 52.5 - Phase 3 HOPE-B trial of etranacogene dezaparvovec in severe/moderately severe hemophilia B: A post hoc responder analysis of participants who received full dose and responded to treatment
Tuesday, June 27, 202311:45 – 12:00 ET
